Avanir Pharmaceuticals has taken a step to push Zenvia, its late-stage investigational drug for pseudobulbar affect (PBA) further along the regulatory pipeline. The Aliso Viejo, Calif.-based company reached out to investors Wednesday with a $40 million registered direct offering to complete development of the drug. (BioWorld Today) Read More
